Reprint

Crosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry

Edited by
June 2022
266 pages
  • ISBN978-3-0365-4001-6 (Hardback)
  • ISBN978-3-0365-4002-3 (PDF)

This book is a reprint of the Special Issue Crosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This Special Issue highlights the most recent research on depression, anxiety and dementia, with attention to comorbidity in a range of diseases. The symptoms of depression, anxiety and dementia are the most common comorbid manifestations present in patients suffering from neurodegenerative and psychiatric diseases. Together, these illnesses constitute an extremely complex and challenging research field due to their inherent multifactorial causative factors, heterogeneous pathogenesis, and mental and behavioral manifestations. This Special Issue covers laboratory, clinical and statistical studies on the crosstalk between depression, anxiety, dementia, Alzheimer’s disease, multiple sclerosis, schizophrenia, diabetes mellitus, Down’s syndrome, and/or compulsive disorders. It contains contributions from 71 authors, has been reviewed by 25 referees, and edited by three academic editors and one managing editor.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
dementia; behavioral and psychological symptoms of dementia; systematic review; meta-analysis; animal-assisted intervention; pet-robot intervention; G protein-coupled receptors; GPR120; FFAR4; schizophrenia; polyunsaturated fatty acids; long-chain fatty acids; omega-3; nutritional psychiatry; Alzheimer’s disease; psychiatric disease; depression; anxiety; Down’s syndrome; inositol; nutraceutical; insulin signaling; antioxidant; aging; psilocybin; depression; anxiety; clinical trials; systematic review; meta-analysis; oxidative stress; redox; antioxidant; multiple sclerosis; biomarker; neurodegenerative disease; personalized medicine; major depressive disorder; longitudinal study; LC-MS/MS; plasma protein biomarker; drug response monitoring; multiple reaction monitoring; dementia; Alzheimer’s disease; depression; diabetes mellitus; type 2; dyslipidemias; hypertension; post-stroke depression; disability level; mortality; depression; late-life depression; dementia; Alzheimer’s disease; neuroimaging; resting-state functional magnetic resonance imaging; default mode network; executive control network; salience network; healthy life expectancy (HALE); morbidity/mortality paradox; anxiety; cognition; systolic blood pressure; cerebral blood flow; arterial properties; angiogenesis; gender medicine; neurodegenerative disorders; kisspeptin; anxiety; locomotion; Kiss1 receptor; HPA axis; HPG axis; nucleus accumbens; depression; anxiety; dementia; Alzheimer’s disease; multiple sclerosis; schizophrenia; stroke; lipid; nutraceutical; diabetes